The same tumor vaccine may be inaccessible to Chinese patients: Ningshi Biotech remakes the antigen.
The same tumor antigen peptide, when entering different patients, has different probabilities of being recognized by T cells. The binding of peptides to MHC molecules is allele-specific, and when switching to another HLA subtype, the originally presentable antigen may fail to bind. This is the most fundamental constraint in the design of therapeutic tumor vaccines, and it is also a part that is easily overlooked for Chinese populations in international pipelines.
Suzhou Ningshi Biotechnology Co., Ltd. builds its products based on this constraint. The company completed industrial and commercial registration at No. 209 Zhuyuan Road, Suzhou High-tech Zone on August 13, 2026, with a registered capital of 2 million RMB and legal representative Zhang Aihan; the registration information from Tianyancha and Qixinbao shows that it is currently held by three natural person shareholders, with no institutional shareholders involved yet. It only has one publicly disclosed pipeline — the population-specific therapeutic tumor vaccine with code name AHV-201, targeting common solid tumors in China, and is seeking a new round of financing.
Population Disparities Overlooked in Antigen Design
Ningshi Biotechnology's judgment in its business plan is that the antigen design of mainstream international vaccine pipelines is based on European and American population cohorts, which has a systematic mismatch with the Chinese population. In terms of allele frequency, the high-frequency HLA-A02:01 in the European population accounts for about 27.1%, while the highest-frequency allele in the Han Chinese population is HLA-A11:01, accounting for about 22.9%; A*02:01 only accounts for about 12% in the Han Chinese population. Antigens selected preferentially according to European and American cohorts may not stably bind to the MHC groove after entering Chinese patients, making it difficult for T cells to be effectively activated.
The differences are not only reflected in the HLA spectrum. Liver cancer in China is predominantly associated with hepatitis B background, and the incidence rates of gastric cancer and esophageal squamous cell carcinoma are significantly higher than those in Europe and the United States, and these cancer types have not been prioritized in international vaccine pipelines for a long time; the difference in somatic mutation spectra means that the presentable mutant antigens for the same cancer type are inconsistent between Chinese and foreign populations. The superposition of three layers of differences makes the practice of directly using antigens from European and American pipelines lack immunological basis.
The volume of the demand side is supported by public data. The 2022 China malignant tumor disease burden data released by the National Cancer Center based on tumor registration and follow-up monitoring shows that there were about 4.8247 million new malignant tumor cases and about 2.5742 million deaths that year. Ningshi Biotechnology initially covers five cancer types: lung cancer, colorectal cancer, liver cancer, gastric cancer and esophageal cancer. According to the company's calculation based on the above mortality data, these five types account for 67.5% of all cancer deaths in total. These five cancer types are also exactly the group with the most obvious differences in etiology between China and foreign countries.
Trade-offs for Fixed Combination, and Cooperative Design of Data-for-Data Exchange
The route selection of AHV-201 is an intermediate solution between matching accuracy and scalability. According to Ningshi Biotechnology's judgment, personalized neoantigen vaccines are highly matched with the patient's own mutation spectrum, but require sequencing, design and preparation on a case-by-case basis, whose cycle and cost cannot cover the scale of Chinese patients; off-the-shelf shared antigen vaccines can be mass-produced with controllable cost, but the antigen selection is relatively rough, lacking population stratification. AHV-201 adopts a fixed multi-epitope antigen combination, sacrificing the matching degree at the individual level in exchange for population-level adaptability and scalability of the fixed combination.
Ningshi Biotechnology has set clear boundaries for its products: it does not sell algorithm platforms or testing services externally, nor does it redesign and produce personalized vaccines for each patient. Its clinical positioning is to be used in combination with PD-1/PD-L1 inhibitors, and the target population is screened through HLA typing, antigen expression, immune microenvironment status and previous treatment history; the indications are not limited to postoperative adjuvant therapy, and the first phase targets patients with advanced, recurrent or progressive disease after standard treatment.
The team has built the screening of candidate antigens into an auditable funnel. 150 candidate antigens are first compressed to 40 through computational optimization, then compressed to 15 through in vitro primary screening with ELISpot of peripheral blood mononuclear cells, and then safety filtering is performed using paired paracancerous samples to exclude antigens expressed in normal tissues, and finally a set of main candidate combinations is frozen with a reserve pool retained. The engineering trade-offs are also specific: low-purity small-batch synthesis is used for rough screening, and high-purity scale-up is only performed for the final 15 selected antigens, so the peptide synthesis cost is controlled at 390,000 RMB.
How many people AHV-201 can cover depends on two thresholds: HLA matching and antigen positivity. Patients first undergo HLA typing, then check the antigen expression, and only those who meet both requirements are included as candidates. This not only determines the accessible population of the product, but also determines the difficulty of future clinical enrollment — this is a question that the fixed combination route must answer on its own, and it is also the price it pays compared to the personalized route.
Preclinical projects are most short of samples, especially paired tumor and paracancerous samples with follow-up outcomes. The practice of Ningshi Biotechnology is to cooperate with tertiary hospitals under the conditions of zero cost, no data outflow and achievement return: it returns the full set of multimodal integrated analysis results to the partners for free, publishes papers with co-authorship, and jointly applies for scientific research funds, in exchange for existing sequencing data, real HLA spectrum of Chinese population, clinical annotations and follow-up outcomes. The cooperation charges no fees, does not require new sampling, does not change the clinical process, the data is stored and analyzed domestically, and will be destroyed as agreed after the cooperation expires. The purpose of this arrangement is to turn the data into auditable and due-diligence-able assets, rather than a one-off project cooperation.
In terms of revenue structure, Ningshi Biotechnology makes it clear that it will not take algorithm services, testing services or research outsourcing as its revenue source, and its value is placed on pharmaceutical assets. Before the application, it will advance through equity financing and strategic cooperation on the basis of candidate combinations, immunological data, animal efficacy and patents; after Phase I, it will negotiate regional licensing, co-development and milestone payments with human safety and immunogenicity data; after Phase II, it will seek global licensing, merger and acquisition or commercialization cooperation with efficacy signals and biomarker population definition. For a preclinical company, each segment of this path is premised on the data of the previous segment, and no step can be skipped.
Six-Person Team, and a Verification Path That Has Not Yet Been Completed
The core team of Ningshi Biotechnology has a total of six members, who are respectively from the University of Oxford, Imperial College London, National University of Singapore, University College London and Peking University, covering antigen science and clinical transformation, antigen preparation and characterization, artificial intelligence modeling, finance and business analysis. CEO Zhang Aihan is a postdoctoral fellow in the Department of Oncology of the University of Oxford and a PhD graduate of University College London; Chief Scientific Officer Shen Jiashu graduated from Peking University with a bachelor's degree, and obtained his PhD and postdoctoral experience at the University of Oxford, and once served as co-founder of a startup and consultant for pharmaceutical companies. The team also disclosed the gaps: there are no full-time personnel in the pharmaceutical and registration modules, and it plans to fill the gap with senior consultants and the recruitment budget of this round.
The progress should be interpreted on the preclinical scale. The company states that the antigen discovery and multimodal integrated analysis pipeline has completed methodological verification on the British cohort, and the construction of the candidate antigen pool and the design of the in vitro verification scheme have been completed. The uncompleted parts are also clear: it has no proprietary human immunogenicity data, no animal efficacy data; the cooperation with many tertiary hospitals is still in the scheme communication stage, and no formal agreement has been signed yet; the first batch of patents is being drafted.
The new round of financing corresponds to an 18- to 24-month pre-application verification path, which sequentially covers candidate discovery and data assets, in vitro primary immunogenicity screening, candidate combination freezing and animal efficacy, CMC lab-scale test and quality research, safety and stability, pre-application documents and Phase I protocol, and sets decision points for continuation or termination at the 6th, 12th and 18th months. The exit criteria are set in advance: if the immunogenicity is insufficient for a long time, it will roll back to the alternative combination or restart the screening; if the safety screening fails, the high-risk antigen will be excluded; if the multi-component preparation cannot be stably prepared, the combination complexity will be reduced; if the positive rate of the target population is too low, the indications will be narrowed.
For investors, what this company can provide now is a set of verifiable methods, a clear cost curve that can be calculated, and a list that clearly states uncompleted items, rather than efficacy conclusions. In the next 18 to 24 months, whether the in vitro immunogenicity, animal efficacy and CMC research can be delivered according to the milestones will determine whether the judgment of designing antigens for the Chinese population can be transformed from a hypothesis to data.